Trevi Therapeutics’ (TRVI) “Buy” Rating Reaffirmed at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of Trevi Therapeutics (NASDAQ:TRVI) in a research report report published on Thursday,Benzinga reports. D. Boral Capital currently has a $19.00 price target on the stock.

A number of other research firms also recently commented on TRVI. Weiss Ratings reiterated a “sell (d-)” rating on shares of Trevi Therapeutics in a research report on Wednesday, October 8th. Leerink Partners lifted their price target on Trevi Therapeutics from $13.00 to $16.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 19th. Stifel Nicolaus boosted their price objective on shares of Trevi Therapeutics from $15.00 to $18.00 and gave the stock a “buy” rating in a research report on Friday, December 19th. B. Riley raised shares of Trevi Therapeutics to a “strong-buy” rating in a research note on Monday, November 17th. Finally, Morgan Stanley lifted their target price on shares of Trevi Therapeutics from $18.00 to $19.00 and gave the stock an “overweight” rating in a research report on Friday, November 14th. Two research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $21.10.

Trevi Therapeutics Stock Performance

Shares of NASDAQ TRVI opened at $11.21 on Thursday. Trevi Therapeutics has a one year low of $3.47 and a one year high of $14.39. The firm has a market capitalization of $1.44 billion, a P/E ratio of -30.30 and a beta of 0.91. The company’s fifty day moving average is $12.20 and its two-hundred day moving average is $9.46.

Trevi Therapeutics (NASDAQ:TRVI) last released its quarterly earnings data on Thursday, November 13th. The company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.02. On average, sell-side analysts forecast that Trevi Therapeutics will post -0.49 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Trevi Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in TRVI. Vivo Capital LLC boosted its stake in Trevi Therapeutics by 28.7% in the 2nd quarter. Vivo Capital LLC now owns 4,487,903 shares of the company’s stock worth $24,549,000 after buying an additional 1,000,000 shares during the last quarter. Prudential Financial Inc. purchased a new position in shares of Trevi Therapeutics during the 2nd quarter worth about $1,238,000. Flputnam Investment Management Co. lifted its holdings in shares of Trevi Therapeutics by 1,105.4% during the 3rd quarter. Flputnam Investment Management Co. now owns 1,048,102 shares of the company’s stock worth $9,590,000 after acquiring an additional 961,150 shares during the period. Jefferies Financial Group Inc. acquired a new stake in shares of Trevi Therapeutics in the second quarter worth approximately $301,000. Finally, AXQ Capital LP purchased a new stake in Trevi Therapeutics in the second quarter valued at approximately $227,000. Hedge funds and other institutional investors own 95.76% of the company’s stock.

About Trevi Therapeutics

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.